Sbi Securities Co., Ltd. Autolus Therapeutics PLC Transaction History
Sbi Securities Co., Ltd.
- $3.48 Trillion
- Q2 2025
A detailed history of Sbi Securities Co., Ltd. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Sbi Securities Co., Ltd. holds 50 shares of AUTL stock, worth $85. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50
Previous 60
16.67%
Holding current value
$85
Previous $93,000
22.58%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AUTL
# of Institutions
100Shares Held
164MCall Options Held
0Put Options Held
39.3K-
Wellington Management Group LLP Boston, MA27.1MShares$46.1 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$34.8 Million0.22% of portfolio
-
Mak Capital One LLC New York, NY17MShares$28.8 Million5.54% of portfolio
-
Deep Track Capital, LP Greenwich, CT16.9MShares$28.6 Million1.36% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$28.3 Million98.24% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $155M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...